News Articles for "Rituximab"
Pfizer halts study of non-Hodgkin's lymphoma drug
Drugmaker Pfizer Inc. has halted a late-stage study of an experimental cancer compound being tested in patients with a certain form of non-Hodgkin's lympho...
read more-
Biogen Idec 1Q income rises on lower tax rate
Biogen Idec Inc. said Thursday its net income climbed 41 percent in the first quarter on lower tax rates and improved sales of its multiple sclerosis drug...
read more
Search Results for "Rituximab"
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | CD20 |
| Clinical data | |
| Trade names | Rituxan |
| AHFS/Drugs.com | monograph |
| Pregnancy cat. | C (US) (no adequate human studies) |
| Legal status | ℞-only (US) |
| Routes | intravenous infusion only (never bolus or "push") |
| Pharmacokinetic data | |
| Bioavailability | 100% (IV) |
| Half-life | 30 to 400 hours (varies by dose and length of treatment) |
| Excretion | Uncertain: may undergo phagocytosis and catabolism in RES |
| Identifiers | |
| CAS number | 174722-31-7  |
| ATC code | L01XC02 |
| DrugBank | DB00073 |
| UNII | 4F4X42SYQ6 |
| KEGG | D02994 |
| ChEMBL | CHEMBL1201576  |
| Chemical data | |
| Formula | C6416H9874N1688O1987S44 |
| Mol. mass | 143859.7 g/mol |
 (what is this?) (verify) |
|
